Document Detail


The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.
MedLine Citation:
PMID:  3046283     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A multicenter randomized trial of anisoylated plasminogen streptokinase activator complex (APSAC) versus heparin in patients with acute myocardial infarction of less than 4 hours' duration was undertaken in 19 hospitals. Of the 313 patients, 151 received heparin and 162 APSAC (30 U as intravenous injection). Within 28 days of hospital stay, 19 deaths (12.6%) occurred in the heparin group and 9 deaths (5.6%) in the APSAC group (p = 0.032). After 24 hours, patients in the APSAC group had a significantly lower incidence of cardiogenic shock (3.2 vs 9.5%, p = 0.031), asystole (3.8 vs 10.8%, p = 0.015) and need for resuscitation (5.1 vs 11.5%, p = 0.039). There was no difference in global and infarct-related ejection fraction between the 2 groups. Thus, APSAC favorably influences prognosis and clinical course in hospital.
Authors:
T Meinertz; W Kasper; M Schumacher; H Just
Related Documents :
10684423 - Characterization of magnesium sulfate as an antiarrhythmic agent.
15773233 - Potassium, magnesium, and electrolyte imbalance and complications in disease management.
10745543 - Electromechanical characterization of acute experimental myocardial infarction.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  62     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1988 Sep 
Date Detail:
Created Date:  1988-09-30     Completed Date:  1988-09-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  347-51     Citation Subset:  AIM; IM    
Affiliation:
Medical Clinic III, University of Freiburg, Federal Republic of Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase
Arteries
Clinical Trials as Topic
Coronary Vessels / physiopathology
Creatine Kinase / blood
Fibrinogen / blood
Heart / physiopathology
Heart Ventricles
Heparin / adverse effects,  therapeutic use*
Humans
Myocardial Infarction / complications,  drug therapy*,  mortality
Plasminogen / adverse effects,  blood,  therapeutic use*
Streptokinase / adverse effects,  therapeutic use*
Vascular Patency
Chemical
Reg. No./Substance:
81669-57-0/Anistreplase; 9001-32-5/Fibrinogen; 9001-91-6/Plasminogen; 9005-49-6/Heparin; EC 2.7.3.2/Creatine Kinase; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Noncardiac surgery in the cardiac patient.
Next Document:  Comparison of coronary stenosis quantitation results from on-line digital and digitized cine film im...